htae39
The lack of patient growth has always been an issue for me.Seasonality in my view does matter much in relation to patients already in therapy.I suspect the upgraded sales force will have an initial positive impact followed by a slowing down in new patient recruits.These numbers are all subjective but they do seem to indicate that together with patient improved discontinuation/persistency rates- patient numbers should grow and remain more stable.Thank you very much for your input.
Kens
Ann: DAYBUE Q1 2025 net sales US$84.6m up 11% from Q1 2024, page-34
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |